Sangamo Therapeutics Appoints Gregory Davis as Vice President, Genome Engineering
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, has appointed Gregory Davis to Vice President, Genome Engineering. ON Partners’ consultant Steve Cornacchia is proud to have partnered with Sangamo Therapeutics and Gregory Davis on this successful placement.
Davis brings 20+ years of biotech R&D leadership experience spanning molecular biology, bioinformatics, and genome editing. He has played key roles in the tech development, intellectual property, and commercialization of three major genome editing technologies, namely RNA-guided group II introns (Targetron), zinc finger nucleases (ZFNs), and CRISPR.
Davis was previously Head of Genome Engineering R&D at MilliporeSigma focused on genome and epigenome editing using RNA-guided group II introns (Targetron), zinc finger nucleases (ZFNs) and CRISPR systems. Prior to that, he spent ten years in R&D at Sigma-Aldrich.
With a robust history of genomic medicine firsts, unmatched technology platform, and growing manufacturing and clinical development capabilities, Sangamo is at the forefront of a new era of genomic medicine.
ON Partners has collaborated with Sangamo Therapeutics on several high-level positions in the past including the placement of the SVP and Chief Medical Officer, Bettina M. Cockroft, MD, MBA.
Read more about our Life Sciences and Healthcare practice and results, including our placement on the Top 50 Life Sciences and Healthcare industry rankings.
ABOUT SANGAMO THERAPEUTICS
Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and genome regulation. For more information about Sangamo, visit www.sangamo.com.
ON Partners propels an organization’s mission by building C-level and board leadership teams. Founded in 2006 by like-minded consultants as a values-driven alternative to the multi-service global firms they were leaving behind, ON delivers a better executive search experience. The firm has been named to the Inc. 500/5000 Lists six times, was named to the Inc. 5000 Hall of Fame in 2018 and is consistently ranked among the top 20 retained executive search firms in the U.S. Find our out more about our Life Sciences and Healthcare practice here.
Find our related successful placements of leading executives here.